Literature DB >> 26682791

Pathogenic Gut Flora in Patients With Chronic Heart Failure.

Evasio Pasini1, Roberto Aquilani2, Cristian Testa3, Paola Baiardi4, Stefania Angioletti3, Federica Boschi5, Manuela Verri2, Francesco Dioguardi6.   

Abstract

OBJECTIVES: The goal of this study was to measure the presence of pathogenic gut flora and intestinal permeability (IP) and their correlations with disease severity, venous blood congestion, and inflammation in patients with chronic heart failure (CHF).
BACKGROUND: Evidence suggests that translocation of gut flora and/or their toxins from the intestine to the bloodstream is a possible trigger of systemic CHF inflammation. However, the relation between pathogenic gut flora and CHF severity, as well as IP, venous blood congestion as right atrial pressure (RAP), and/or systemic inflammation (C-reactive protein [CRP]), is still unknown.
METHODS: This study analyzed 60 well-nourished patients in stable condition with mild CHF (New York Heart Association [NYHA] functional class I to II; n = 30) and moderate to severe CHF (NYHA functional class III to IV; n = 30) and matched healthy control subjects (n = 20). In all subjects, the presence and development in the feces of bacteria and fungi (Candida species) were measured; IP according to cellobiose sugar test results was documented. The study data were then correlated with RAP (echocardiography) and systemic inflammation.
RESULTS: Compared with normal control subjects, the entire CHF population had massive quantities of pathogenic bacteria and Candida such as Campylobacter (85.3 ± 3.7 CFU/ml vs. 1.0 ± 0.3 CFU/ml; p < 0.001), Shigella (38.9 ± 12.3 CFU/ml vs. 1.6 ± 0.2 CFU/ml; p < 0.001), Salmonella (31.3 ± 9.1 CFU/ml vs 0 CFU/ml; p < 0.001), Yersinia enterocolitica (22.9 ± 6.3 CFU/ml vs. 0 CFU/ml; p < 0.0001), and Candida species (21.3 ± 1.6 CFU/ml vs. 0.8 ± 0.4 CFU/ml; p < 0.001); altered IP (10.2 ± 1.2 mg vs. 1.5 ± 0.8 mg; p < 0.001); and increased RAP (12.6 ± 0.6 mm Hg) and inflammation (12.5 ± 0.6 mg/dl). These variables were more pronounced in patients with moderate to severe NYHA functional classes than in patients with the mild NYHA functional class. Notably, IP, RAP, and CRP were mutually interrelated (IP vs. RAP, r = 0.55; p < 0.0001; IP vs. CRP, r = 0.78; p < 0.0001; and RAP vs. CRP, r = 0.78; p < 0.0001).
CONCLUSIONS: This study showed that patients with CHF may have intestinal overgrowth of pathogenic bacteria and Candida species and increased IP associated with clinical disease severity, venous blood congestion, and inflammation.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic heart failure; gut flora; inflammation; intestinal permeability

Mesh:

Substances:

Year:  2015        PMID: 26682791     DOI: 10.1016/j.jchf.2015.10.009

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  106 in total

Review 1.  From obesity through gut microbiota to cardiovascular diseases: a dangerous journey.

Authors:  Paolo Marzullo; Laura Di Renzo; Gabriella Pugliese; Martina De Siena; Luigi Barrea; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano
Journal:  Int J Obes Suppl       Date:  2020-07-20

Review 2.  The gut microbiome and heart failure: A better gut for a better heart.

Authors:  Maxime Branchereau; Rémy Burcelin; Christophe Heymes
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

Review 3.  Targeting the Microbiome in Heart Failure.

Authors:  Allyson Zabell; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

4.  Following the Scent of Microbes Within: The Heart-Gut Connection.

Authors:  Chonyang Lu Albert; W H Wilson Tang
Journal:  J Card Fail       Date:  2019-03-26       Impact factor: 5.712

Review 5.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

Review 6.  Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.

Authors:  Yana Anfinogenova; Elena V Grakova; Maria Shvedova; Kristina V Kopieva; Alexander T Teplyakov; Sergey V Popov
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

7.  Portal congestion and intestinal edema in hospitalized patients with heart failure.

Authors:  Yuki Ikeda; Shunsuke Ishii; Mayu Yazaki; Teppei Fujita; Yuichiro Iida; Toyoji Kaida; Takeru Nabeta; Eiji Nakatani; Emi Maekawa; Tomoyoshi Yanagisawa; Toshimi Koitabashi; Takayuki Inomata; Junya Ako
Journal:  Heart Vessels       Date:  2018-01-11       Impact factor: 2.037

Review 8.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

Review 9.  Gut Microbiota in Cardiovascular Health and Disease.

Authors:  W H Wilson Tang; Takeshi Kitai; Stanley L Hazen
Journal:  Circ Res       Date:  2017-03-31       Impact factor: 17.367

Review 10.  T-cell recruitment to the heart: friendly guests or unwelcome visitors?

Authors:  Robert M Blanton; Francisco J Carrillo-Salinas; Pilar Alcaide
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-10       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.